Key result
PTSMA eliminates symptoms at 1 year in recurrent HOCM following surgical myectomy.
Why the study?
Percutaneous transluminal septal myocardial ablation is an alternative to surgical myectomy for severe, drug-refractory hypertrophic obstructive cardiomyopathy with limited data on its use after prior myectomy.
Case Report (n=1)
Percutaneous transluminal septal myocardial ablation can be a successful treatment option for patients with HOCM who experience disease progression after surgical myectomy.
May support PTSMA after failed myectomy in select HOCM cases; leaves open need for prospective trials.
Hypertrophic obstructive cardiomyopathy (HOCM) is a primary, usually familial and genetically fixed myocardial hypertrophy, with dynamic left ventricular outflow tract obstruction. An alternative to surgical myectomy in the treatment of severe, drug refractory, HOCM is percutaneous transluminal septal myocardial ablation (PTSMA). We report a case of 24 year old female patient who had the first septal myectomy but because of progression of her disease, the percutaneous treatment of hypertrophic obstructive cardiomyopathy was performed. A year after the PTSMA the patient was without of symptoms.
No takes yet. Share an insight, caveat, or question.
Kulić et al. (2010) conducted a case report in Hypertrophic obstructive cardiomyopathy (HOCM) (n=1). Percutaneous transluminal septal myocardial ablation (PTSMA) was evaluated on Symptom status. Percutaneous transluminal septal myocardial ablation successfully eliminated symptoms at 1 year in a patient with progressive hypertrophic obstructive cardiomyopathy after surgical myectomy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: